TACTILE SYSTEMS TECHNOLOGY I (TCMD) Stock Fundamental Analysis
NASDAQ:TCMD - Nasdaq - US87357P1003 - Common Stock - Currency: USD
Overall TCMD gets a fundamental rating of 6 out of 10. We evaluated TCMD against 189 industry peers in the Health Care Equipment & Supplies industry. While TCMD has a great health rating, its profitability is only average at the moment. TCMD may be a bit undervalued, certainly considering the very reasonable score on growth With these ratings, TCMD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year TCMD was profitable.
In the past year TCMD had a positive cash flow from operations.
In multiple years TCMD reported negative net income over the last 5 years.
Each year in the past 5 years TCMD had a positive operating cash flow.
1.2 Ratios
The Return On Assets of TCMD (5.69%) is better than 86.24% of its industry peers.
TCMD's Return On Equity of 7.83% is amongst the best of the industry. TCMD outperforms 83.07% of its industry peers.
TCMD has a better Return On Invested Capital (6.23%) than 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.69% | ||
| ROE | 7.83% | ||
| ROIC | 6.23% |
ROA(3y)2.94%
ROA(5y)0.73%
ROE(3y)2.6%
ROE(5y)-0.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TCMD has a better Profit Margin (5.79%) than 77.78% of its industry peers.
TCMD's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 7.57%, TCMD is in the better half of the industry, outperforming 75.66% of the companies in the same industry.
In the last couple of years the Operating Margin of TCMD has grown nicely.
TCMD has a Gross Margin (51.35%) which is in line with its industry peers.
TCMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.57% | ||
| PM (TTM) | 5.79% | ||
| GM | 51.35% |
OM growth 3YN/A
OM growth 5Y6.44%
PM growth 3YN/A
PM growth 5Y-0.06%
GM growth 3Y3.35%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TCMD is destroying value.
The number of shares outstanding for TCMD has been increased compared to 1 year ago.
The number of shares outstanding for TCMD has been increased compared to 5 years ago.
TCMD has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.68 indicates that TCMD is not in any danger for bankruptcy at the moment.
TCMD's Altman-Z score of 3.68 is fine compared to the rest of the industry. TCMD outperforms 74.60% of its industry peers.
TCMD has a debt to FCF ratio of 0.69. This is a very positive value and a sign of high solvency as it would only need 0.69 years to pay back of all of its debts.
TCMD has a better Debt to FCF ratio (0.69) than 93.12% of its industry peers.
TCMD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TCMD (0.11) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 3.68 |
ROIC/WACC0.73
WACC8.57%
2.3 Liquidity
TCMD has a Current Ratio of 4.36. This indicates that TCMD is financially healthy and has no problem in meeting its short term obligations.
TCMD has a Current ratio of 4.36. This is in the better half of the industry: TCMD outperforms 67.20% of its industry peers.
TCMD has a Quick Ratio of 3.90. This indicates that TCMD is financially healthy and has no problem in meeting its short term obligations.
TCMD's Quick ratio of 3.90 is fine compared to the rest of the industry. TCMD outperforms 69.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.36 | ||
| Quick Ratio | 3.9 |
3. Growth
3.1 Past
The earnings per share for TCMD have decreased strongly by -45.45% in the last year.
Measured over the past 5 years, TCMD shows a small growth in Earnings Per Share. The EPS has been growing by 4.86% on average per year.
TCMD shows a small growth in Revenue. In the last year, the Revenue has grown by 6.76%.
Measured over the past years, TCMD shows a quite strong growth in Revenue. The Revenue has been growing by 9.11% on average per year.
EPS 1Y (TTM)-45.45%
EPS 3YN/A
EPS 5Y4.86%
EPS Q2Q%-62.5%
Revenue 1Y (TTM)6.76%
Revenue growth 3Y12.08%
Revenue growth 5Y9.11%
Sales Q2Q%0.3%
3.2 Future
The Earnings Per Share is expected to grow by 30.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.53% on average over the next years. This is quite good.
EPS Next Y-7.34%
EPS Next 2Y12.76%
EPS Next 3Y30.58%
EPS Next 5YN/A
Revenue Next Year8.57%
Revenue Next 2Y8.7%
Revenue Next 3Y9.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.61, the valuation of TCMD can be described as correct.
84.66% of the companies in the same industry are more expensive than TCMD, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of TCMD to the average of the S&P500 Index (23.99), we can say TCMD is valued slightly cheaper.
The Price/Forward Earnings ratio is 10.68, which indicates a very decent valuation of TCMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TCMD indicates a rather cheap valuation: TCMD is cheaper than 90.48% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TCMD to the average of the S&P500 Index (20.35), we can say TCMD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.61 | ||
| Fwd PE | 10.68 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TCMD is valued cheaply inside the industry as 97.88% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TCMD is valued cheaper than 98.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.98 | ||
| EV/EBITDA | 4.73 |
4.3 Compensation for Growth
TCMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as TCMD's earnings are expected to grow with 30.58% in the coming years.
PEG (NY)N/A
PEG (5Y)3
EPS Next 2Y12.76%
EPS Next 3Y30.58%
5. Dividend
5.1 Amount
No dividends for TCMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.64
-0.26 (-2.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.76%
Inst Owner Change-0.17%
Ins Owners1.72%
Ins Owner Change3.28%
Market Cap228.18M
Analysts78.18
Price Target16.32 (69.29%)
Short Float %9.53%
Short Ratio8.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.38%
Min EPS beat(2)15.79%
Max EPS beat(2)24.97%
EPS beat(4)4
Avg EPS beat(4)30.17%
Min EPS beat(4)15.79%
Max EPS beat(4)53.45%
EPS beat(8)8
Avg EPS beat(8)444.14%
EPS beat(12)9
Avg EPS beat(12)287.89%
EPS beat(16)11
Avg EPS beat(16)199.03%
Revenue beat(2)0
Avg Revenue beat(2)-3.74%
Min Revenue beat(2)-5.72%
Max Revenue beat(2)-1.76%
Revenue beat(4)1
Avg Revenue beat(4)-1.92%
Min Revenue beat(4)-5.72%
Max Revenue beat(4)1.21%
Revenue beat(8)3
Avg Revenue beat(8)-0.27%
Revenue beat(12)7
Avg Revenue beat(12)1.22%
Revenue beat(16)10
Avg Revenue beat(16)0.58%
PT rev (1m)15.69%
PT rev (3m)-6.35%
EPS NQ rev (1m)4.37%
EPS NQ rev (3m)-90.22%
EPS NY rev (1m)-3.24%
EPS NY rev (3m)-25.09%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-5.4%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.61 | ||
| Fwd PE | 10.68 | ||
| P/S | 0.78 | ||
| P/FCF | 5.98 | ||
| P/OCF | 5.61 | ||
| P/B | 1.05 | ||
| P/tB | 1.6 | ||
| EV/EBITDA | 4.73 |
EPS(TTM)0.66
EY6.85%
EPS(NY)0.9
Fwd EY9.36%
FCF(TTM)1.61
FCFY16.72%
OCF(TTM)1.72
OCFY17.82%
SpS12.38
BVpS9.15
TBVpS6.03
PEG (NY)N/A
PEG (5Y)3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.69% | ||
| ROE | 7.83% | ||
| ROCE | 8.62% | ||
| ROIC | 6.23% | ||
| ROICexc | 10.8% | ||
| ROICexgc | 21.51% | ||
| OM | 7.57% | ||
| PM (TTM) | 5.79% | ||
| GM | 51.35% | ||
| FCFM | 13.02% |
ROA(3y)2.94%
ROA(5y)0.73%
ROE(3y)2.6%
ROE(5y)-0.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y15.26%
ROICexc growth 3YN/A
ROICexc growth 5Y1.86%
OM growth 3YN/A
OM growth 5Y6.44%
PM growth 3YN/A
PM growth 5Y-0.06%
GM growth 3Y3.35%
GM growth 5Y-0.43%
F-Score8
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 0.69 | ||
| Debt/EBITDA | 0.8 | ||
| Cap/Depr | 36.94% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 10.53 | ||
| Cash Conversion | 140.32% | ||
| Profit Quality | 224.92% | ||
| Current Ratio | 4.36 | ||
| Quick Ratio | 3.9 | ||
| Altman-Z | 3.68 |
F-Score8
WACC8.57%
ROIC/WACC0.73
Cap/Depr(3y)35.17%
Cap/Depr(5y)50.34%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.45%
EPS 3YN/A
EPS 5Y4.86%
EPS Q2Q%-62.5%
EPS Next Y-7.34%
EPS Next 2Y12.76%
EPS Next 3Y30.58%
EPS Next 5YN/A
Revenue 1Y (TTM)6.76%
Revenue growth 3Y12.08%
Revenue growth 5Y9.11%
Sales Q2Q%0.3%
Revenue Next Year8.57%
Revenue Next 2Y8.7%
Revenue Next 3Y9.53%
Revenue Next 5YN/A
EBIT growth 1Y22.95%
EBIT growth 3YN/A
EBIT growth 5Y16.13%
EBIT Next Year71.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.3%
FCF growth 3Y420.83%
FCF growth 5YN/A
OCF growth 1Y13.39%
OCF growth 3Y149.11%
OCF growth 5Y74.54%